Table 1 Characteristics of the 411 patients included in the study.
From: Association of VAV2 and VAV3 polymorphisms with cardiovascular risk factors
N | % | |
|---|---|---|
Sex | ||
Female | 192 | 47.2 |
Male | 215 | 52.1 |
HT | ||
Yes | 209 | 50.9 |
No | 202 | 49.1 |
Diabetes Mellitus | ||
Yes | 66 | 83.5 |
No | 345 | 16.0 |
Pathologic state | ||
Yes | 281 | 31.5 |
No | 130 | 68.0 |
Target organ damage | ||
Yes | 191 | 46.2 |
No | 220 | 53.3 |
Altered basal glycaemia | ||
Yes | 51 | 12.3 |
No | 360 | 87.2 |
BMI | ||
BMI < 25 | 74 | 17.9 |
BMI 25–30 | 210 | 50.8 |
BMI > 30 | 127 | 30.8 |
Dyslipidemia | ||
Yes | 386 | 93.5 |
No | 24 | 5.8 |
Elevated PP | ||
Yes | 97 | 23.5 |
No | 314 | 76.0 |
LVH | ||
Yes | 34 | 8.2 |
No | 367 | 88.9 |
C-IMT | ||
Yes | 73 | 17.7 |
No | 336 | 81.4 |
Altered PWV | ||
Yes | 63 | 15.3 |
No | 343 | 83.1 |
PAD | ||
Yes | 7 | 1.7 |
No | 402 | 98.3 |
CV risk | ||
<1% | 58 | 14.1 |
1–5% | 198 | 48.2 |
5–10% | 84 | 20.4 |
>10% | 71 | 17.3 |
Antihypertensive drugs | ||
Yes | 227 | 55.0 |
No | 184 | 44.6 |
Antidiabetic drugs | ||
Yes | 66 | 16.0 |
No | 345 | 83.5 |
Lipid-lowering drugs | ||
Yes | 164 | 39.7 |
No | 247 | 59.8 |
